Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer.
The toxicities of oral Ftorafur (1 g/m2/day 1-21) and intravenous 5-fluorouracil (5-FU) (500 mg/m2/day 1-5) were compared in a prospective randomized study in patients with colorectal cancer. The treatment courses were repeated every 6th week. Leucopenia was more common after 5-FU. Leucocyte nadir in connection with first treatment cycle was on average seen on day 15 in patients receiving 5-FU and on day 28 in patients receiving Ftorafur. Significantly more patients on 5-FU developed stomatitis. There was no difference in the number of patients with diarrhea or nausea/vomiting. Median survival and response rates were not significantly different after the two treatment schedules.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*
D005641:Tegafur; D005472:Fluorouracil